[Low-dose fish oil in primary hypertriglyceridemia. A randomized placebo-controlled study].

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Primary hypertriglyceridemia is a condition characterized by elevated triglyceride levels.
• Effective and safe therapeutic options for managing hypertriglyceridemia are continuously sought.
• Fish oil, rich in omega-3 fatty acids, is a potential agent for lipid management.

Purpose of the Study:

• To evaluate the efficacy of two low doses of fish oil in managing primary hypertriglyceridemia.
• To assess the impact of fish oil on serum triglyceride levels, cholesterol, alkaline phosphatase, and platelet aggregation.
• To compare the effects of 10.5 g and 5.25 g daily doses of fish oil against a placebo.

Main Methods:

• A double-blind, randomized, placebo-controlled trial was conducted.
• Patients received either 10.5 g or 5.25 g of fish oil daily in capsule form, or a placebo, for six weeks.
• Serum triglyceride levels, total and HDL-cholesterol, alkaline phosphatase, and collagen-induced platelet aggregation were measured.

Main Results:

• The 10.5 g daily dose of fish oil significantly reduced serum triglycerides by 38% (p<0.05).
• The 5.25 g daily dose resulted in a 20% triglyceride reduction (not significant).
• A significant decrease in serum alkaline phosphatase (12%, p<0.01) and inhibition of platelet aggregation were observed with the 10.5 g dose.

Conclusions:

• A daily dose of 10.5 g of fish oil is effective in significantly reducing triglyceride levels in patients with primary hypertriglyceridemia.
• Fish oil at this dose also demonstrates beneficial effects on alkaline phosphatase and platelet aggregation.
• The lower dose of 5.25 g daily was not found to be significantly effective in lowering triglyceride levels.